Pressure Biosciences (PBIO) AI Stock Analysis

• Market Cap: $520.28K
• Dividend Yield: N/A
• Average Volume (3M): 3.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -7.15
• Revenue Growth: -20.28%
• EPS Growth: 13.56%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 77
• Industry: Medical Equipment & Supplies
• EPS (TTM): -0.95
• Shares Outstanding: 40,967,083
• 10 Day Avg. Volume: 2,612
• 30 Day Avg. Volume: 3,243
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.35
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pressure Biosciences' score reflects significant financial instability with high leverage and negative cash flows. The absence of positive technical indicators and valuation metrics further weighs on the stock. The lack of guidance or sentiment from the earnings call adds uncertainty, limiting any positive outlook in the near term.

Pressure Biosciences Business Overview & Revenue Model

Company Description

Pressure BioSciences, Inc. (PBIO) is a life sciences company focused on developing and commercializing innovative technologies and products for the global healthcare, biotechnology, pharmaceutical, and food industries. The company specializes in high-pressure-based scientific instruments and associated consumables, which are used for various applications, including biomarker discovery, drug design, food safety, and pathogen inactivation. PBIO's core technology platform, Pressure Cycling Technology (PCT), enables the manipulation of biomolecules and cellular structures in a unique manner, enhancing the quality and efficiency of scientific research and development.

How the Company Makes Money

Pressure BioSciences generates revenue primarily through the sale of its proprietary high-pressure instruments and consumable products. The company markets its Pressure Cycling Technology (PCT) systems to research institutions, biotechnology and pharmaceutical companies, and government entities. Revenue streams include direct sales of instruments, recurring sales of consumables required for ongoing use of the systems, and service contracts for maintenance and support of the equipment. Additionally, PBIO may engage in collaborative partnerships and licensing agreements that provide funding and the potential for milestone payments and royalties. The company's growth is supported by its focus on expanding applications for its technology across various sectors, thereby increasing its customer base and market penetration.

Pressure Biosciences Financial Statement Overview

Summary

Pressure Biosciences is facing significant financial challenges with negative net income, high debt levels, negative cash flows, and negative stockholders' equity, indicating financial instability and ongoing profitability issues.

Income Statement

Pressure Biosciences has shown some revenue growth from 2022 to 2023, but consistently negative net income and EBIT margins indicate ongoing profitability challenges. The net profit margin remains deeply negative, reflecting significant expenses relative to revenue.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets, a concerning financial position. The high debt levels relative to equity suggest financial instability and potential difficulty in meeting long-term obligations.

Cash Flow

Operating cash flow is negative and free cash flow has not shown improvement, indicating cash generation issues. The company relies heavily on financing activities to support operations, which may not be sustainable long-term.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.50M	1.98M	1.73M	2.00M	1.22M	1.81M
	Gross Profit
421.66M	799.56K	-284.66K	1.06M	637.74K	612.93K
	EBIT
-8.61M	-9.50M	-4.90M	-4.19M	-4.59M	-5.81M
	EBITDA
-10.83M	-9.39M	-5.40M	-5.53M	-7.46M	-6.41M
	Net Income Common Stockholders
-31.36M	-29.31M	-16.82M	-34.60M	-24.35M	-11.66M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
81.28K	81.28K	3.87K	132.31K	18.54K	29.63K
	Total Assets
1.05M	1.05M	2.01M	2.83M	2.30M	1.82M
	Total Debt
23.89M	22.89M	20.53M	14.64M	9.60M	7.96M
	Net Debt
23.80M	22.80M	20.53M	14.51M	9.58M	7.93M
	Total Liabilities
33.80M	33.80M	34.70M	25.04M	19.22M	13.87M
	Stockholders Equity
-32.75M	-32.75M	-32.69M	-22.21M	-16.92M	-12.06M
Cash Flow		Free Cash Flow
-2.57B	-3.19M	-4.50M	-4.99M	-4.88M	-6.35M
	Operating Cash Flow
-2.57B	-3.19M	-4.48M	-4.87M	-4.88M	-6.33M
	Investing Cash Flow
-7.49M	-7.50K	-20.75K	-122.94K	-796.66K	-23.38K
	Financing Cash Flow
2.50B	3.27M	4.37M	5.11M	5.67M	6.28M

Pressure Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECH	73 Outperform	$9.83B	60.86	7.82%	0.53%	4.46%	-29.62%
TMO	70 Outperform	$196.95B	30.77	13.15%	0.31%	0.05%	6.87%
MDXG	70 Outperform	$1.17B	27.84	25.01%	―	8.52%	-32.91%
BIO	49 Neutral	$7.14B	―	-24.09%	―	-3.92%	-202.80%
Sector *	49 Neutral	$6.87B	0.03	-54.93%	2.50%	24.65%	-2.90%
QDEL	46 Neutral	$2.44B	―	-50.74%	―	-7.03%	-20233.78%
PBIO	32 Underperform	$520.28K	―	89.50%	―	-20.28%	13.56%